Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?. (26th July 2018)

• Record Type: Journal Article
• Authors: Yaro, Seydou; Njanpop Lafourcade, Berthe-Marie; Ouangraoua, Soumeya; Ouoba, Aline; Kpoda, Hervé; Findlow, Helen; Tall, Haoua; Seanehia, Joy; Martin, Catherine; Ouedraogo, Jean-Bosco; Gessner, Bradford; Meda, Nicolas; Borrow, Ray; Trotter, Caroline; Mueller, Judith E
• Is Part Of: Clinical infectious diseases. Volume 68:Number 3(2019)
• Page Start: 435
• Page End: 443
• Publication Date: 2018-07-26
• Subjects: Neisseria meningitides -- serogroup A -- conjugate vaccine -- seroepidemiological studies -- sub-Saharan Africa; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciy488
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: In Burkina Faso, serogroup A meningococcal (NmA) conjugate vaccine (PsA-TT, MenAfriVac) was introduced through a mass campaign in children and adults in December 2010. Similar to a serological survey in 2011, we followed population-level antibody persistence for 5 years after the campaign and estimated time of return to previously-published pre-vaccination levels. Methods: We conducted 2 cross-sectional surveys in 2013 and early 2016, including representative samples (N = 600) of the general population of Bobo-Dioulasso, Burkina Faso. Serum bactericidal antibody titers (rabbit complement) were measured against NmA reference strain F8236 (SBA-ref), NmA strain 3125 (SBA-3125), and NmA–specific immunoglobulin G (IgG) concentrations. Results: During the 2016 survey, in different age groups between 6 and 29 years, the relative changes in geometric means compared to 2011 values were greater among younger age groups. They were between -87% and -43% for SBA-ref; -99% and -78% for SBA-3125; and -89% and -63% for IgG. In linear extrapolation of age-specific geometric means from 2013 to 2016, among children aged 1– 4 years at the time of the PsA-TT campaign, a return to pre-vaccination levels should be expected after 12, 8, and 6 years, respectively, according to SBA-ref, SBA-3125, and IgG. Among older individuals, complete return to baseline is expected at the earliest after 11 years (SBA-ref and SBA-3125) or 9 years (IgG). Conclusions: Based on SBA-3125, a booster campaign after 8 years would be required to sustain direct immune protection for children aged 1–4 years during the PsA-TT campaign. Antibodies persisted longer in older age groups. Abstract : Based on population-level serum bactericidal antibody persistence against strain 3125 in 5 years of data following the Burkina-Faso MenAfriVac campaign, an 8-year booster would be required to ensure protection for children who were aged 1–4 years during the campaign.